Pharm 101: Irbesartan


Angiotensin-II Receptor Bloker

  • Competitive selective antagonist of angiotensin II type 1 (AT1) receptor
  • Causes vasodilation and inhibition of aldosterone secretion
  • More selective blockers of angiotensin effects than ACE-I, benefits include:
    • More complete inhibition of angiotensin action, because there are enzymes other than ACE capable of generating angiotensin II
    • No effect on bradykinin metabolism so reduced incidence of cough, angioedema

  • 90% protein bound
  • Half-life 12 hours
  • Liver metabolism

Clinical uses
  • Hypertension
  • CCF
  • Chronic renal failure:
    • Diminish proteinuria and stabilise renal function (even in absence of lowering BP)

Adverse effects
  • Similiar to those of ACE-inhibitors, except for cough and angioedema which are uncommon

  • Non-diabetic renal failure
  • Pregnancy
  • Hyperkalaemia
  • Renal artery stenosis

Further Reading

Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS (UWA) CCPU Emergency Medicine Trainee with interests in medical education, ECG interpretation, and the use of point-of-care ultrasound in the undifferentiated patient. Co-author of the LITFL ECG Library | Twitter

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.